Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT

Ashley V. Geerlinks, Brooks Scull, Christa Krupski, Ryan Fleischmann, Michael A. Pulsipher, Mary Eapen, James A. Connelly, Catherine M. Bollard, Sung Yun Pai, Christine N. Duncan, Leslie S. Kean, K. Scott Baker, Lauri M. Burroughs, Jeffrey R. Andolina, Shalini Shenoy, Philip Roehrs, Rabi Hanna, Julie An Talano, Kirk R. Schultz, Elizabeth O. StengerHoward Lin, Adi Zoref-Lorenz, Kenneth L. McClain, Michael B. Jordan, Tsz Kwong Man, Carl E. Allen, Rebecca A. Marsh

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT'. Together they form a unique fingerprint.

Keyphrases

Immunology and Microbiology